Actinium Pharmaceuticals, Inc., is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. We look forward to 2016 and beyond with confidence, "said Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals. Actinium Pharmaceuticals, Inc. is a New York- base
-Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder and Fragile X Syndrome, today announced participation in a panel titled "Underdiscovered NeuroInnovators" at the Piper Jaffray 27th Annual Healthcare Conference
Amgen today announced the submission of a Biologics License Application with the United States Food and Drug Administration for ABP 501, a biosimilar candidate to Humira . Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen's first BLA submission using the 351 biosimilar pathwa
-Amphastar Pharmaceuticals, Inc. announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 11:30 a.m. Eastern Standard Time in New York, NY. This press release contains forward-looking statements, including statements relating to Amph
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer s disease, other central nervous system diseases, pain and various types of cancer, announces that Kristina M. Capiak, CCRP has been promoted the Company s Vice President of Regulatory Affairs. Ms. Capiak has more than 10 yea
Deal Type: Venture Financing Deal Sub Type: Start Up Deal Country: United States of America Deal Status: Announced Deal Value: 7.0000 USD. Appco Pharma LLC, a generic pharmaceutical company, has announced to raise USD3 million in venture financing round. Index- Drug Manufacturing Index- Generics Index- API Manufacturers Index- United States of Amer
Deal Type: Venture Financing Deal Sub Type: Growth Capital/Expansion Deal Country: United States of America Deal Status: Completed Deal Value: 3.0000 USD. Aridis Pharmaceutical, LLC., a biotechnology company, has raised USD3 million of its planned USD3.5 million financing round. Index- Contract Manufacturers Index- Drug Discovery Index- Infectious
LOS ANGELES, CA/ ACCESSWIRE/ November 16, 2015/ Cell Source, Inc., a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine today announced that it will be presenting at the 8th annual LD Micro Main Event on Thursday, December3rd at 4 PM PST. Cell Source, Inc. is a biotechnology company
Despite a promise from its chief executive two months ago, Turing Pharmaceuticals said Wednesday it has decided to keep the price of an anti-infection drug high a sustained increase that generated a national outcry among patients this summer. The hike took the cost of Daraprim from about $13 per tablet to $750 per tablet a 5,000 percent increas
This determination will allow FDA to approve abbreviated new drug applications for TYLENOL WITH CODEINE oral tablets, 325 mg/7. 5 mg, 325 mg/15 mg, 325 mg/30 mg, and 325 mg/60 mg, if all other legal and regulatory requirements are met. The 1984 amendments include what is now section 505 of the Federal Food, Drug, and Cosmetic Act, which requires FD
By a News Reporter-Staff News Editor at Biotech Week Dyax Corp. announced that two oral presentations describing clinical data from its DX-2930 Phase 1 b study were presented at the American College of Allergy, Asthma, and Immunology Annual Meeting taking place in San Antonio, Texas. "We are pleased to have our Phase 1 b DX-2930 data selected fo
EDDA Technology, a global leading provider in advanced imaging-guided precision treatment solutions, announced today that the company has received FDA clearance on IQQA - Guide, a system that supports intra-operative precision 3 D navigation for surgical procedures of thoracic, abdominal, and pelvic soft-organs. "With the latest FDA clearance,
Endo International plc today announced that Rajiv De Silva, President and CEO, will discuss corporate updates at the 27 th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 2, 2015 at 1 p.m. ET. Endo International plc is a global specialty pharmaceutical company focused on improving patients' lives while creating share
Federal health officials have approved a first-of-a-kind flu vaccine that contains a booster to help protect seniors vulnerable to the virus. The Food and Drug Administration says Fluad is the first seasonal vaccine that contains an adjuvant, a substance that boosts the body's immune response. The vaccine was first approved in Italy in 1997 and
Toronto, Ontario- Theralase Technologies Inc., a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that the Food and Drug Administration has granted 510 approval for Theralase s next generation therapeutic laser, the TLC -2000 Therapeutic Medical Laser System.
Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce that the U.S. Food and Drug Administration has granted Fast Track Designation for Brilacidin-OM, an oral rinse formulation of the Company's novel...
BASEL- The U.S. Food and Drug Administration approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad was first approved for use in Italy in 1997 and is currently approved in 38 countries, including Canada and 15 European countries. Fluad and Agriflu are manufactured by Novartis Vaccines and Diagnostics Limited, an affilia
Findings from Food and Drug Administration Provides New Data about Pharmacokinetics. Our news editors obtained a quote from the research from Food and Drug Administration, "The current review explores the possibility of developing appropriate bioequivalence approaches based on pharmacokinetic principles for topical dermatological products.
By a News Reporter-Staff News Editor at Biotech Week Sarah R. London and Paulina do Amaral of the national plaintiffs' law firm Lieff Cabraser Heimann& Bernstein, LLP, announce that Robin and Stanley Zgurski, residents of Florida, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC for the injuries suffered by th
By a News Reporter-Staff News Editor at Biotech Week FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of transformative medicines to treat serious brain diseases, announced that the U.S. Food and Drug Administration has removed a partial clinical hold on the Phase 3 encenicline program for
Lannett Co. Inc. might be a takeover target or a buyer in the future, but it is now trying to digest a complicated acquisition of its own from September and a smaller one from May. Lannett, with 502 employees and five Philadelphia properties, was formed by two pharmacist brothers in 1942, before there was a distinct generic-drug industry. Today, wi
-GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW's Chief Executive Officer, will present at the Piper Jaffray 27th Annual Healthcare Conference to be held at the Lotte New York Palace
?10 partner programs with' Abzena inside' technology now in clinical development? Gilead's GS-5745 progressed into Phase III with ongoing trials also in ulcerative colitis and Crohn's Disease? Post period end, developer of' Abzena inside' product SDP051, Adheron Therapeutics acquired by Roche for up to $580 m- SDP051 will now move into Phase
ALEXANDRIA, Va., Nov. 25 Hedgepath Pharmaceuticals, Tampa, Florida, has been assigned a patent developed by two co-inventors for a "treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors." The co-inventors are Nicholas J. Virca, Tampa, Florida, and Francis E. O'Donnell Jr., Longboat Key, Florida. Written